T-cell-independent Antitumor Effects of CD40 Ligation

Por Rakhmilevich, Alexander L., Alderson, Kory L., Sondel, Paul M.
Publicado em 2012

Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides

Por Buhtoiarov, Ilia N, Sondel, Paul M, Eickhoff, Jens C, Rakhmilevich, Alexander L
Publicado em 2007

Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages

Por Shi, Yongyu, Felder, Mildred A.R., Sondel, Paul M., Rakhmilevich, Alexander L.
Publicado no Mol Immunol (2015)

Tumoricidal Effects of Activated Macrophages in a Mouse Model of Chronic Lymphocytic Leukemia

Por Wu, Qing-Li, Buhtoiarov, Ilia N., Sondel, Paul M., Rakhmilevich, Alexander L., Ranheim, Erik A.
Publicado em 2009

Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model

Por Qu, Xiaoyi, Felder, Mildred A.R., Horta, Zulmarie Perez, Sondel, Paul M., Rakhmilevich, Alexander L.
Publicado em 2013

Synergistic inhibition of tumor growth in a murine mammary adenocarcinoma model by combinational gene therapy using IL-12, pro-IL-18, and IL-1β converting enzyme cDNA

Por Oshikawa, Katsuhisa, Shi, Fushun, Rakhmilevich, Alexander L., Sondel, Paul M., Mahvi, David M., Yang, Ning-Sun
Publicado em 1999

Intratumoral delivery of low doses of anti-CD40 mAb combined with monophosphoryl lipid A induces local and systemic antitumor effects in immunocompetent and T cell-deficient mice

Por Van De Voort, Tyler J., Felder, Mildred A. R., Yang, Richard K., Sondel, Paul M., Rakhmilevich, Alexander L.
Publicado em 2013

Enhancement of the anti-melanoma response of Hu14.18K322A by αCD40 + CpG

Por Alderson, Kory L., Luangrath, Mitchell, Elsenheimer, Megan M., Gillies, Stephen D., Navid, Fariba, Rakhmilevich, Alexander L., Sondel, Paul M.
Publicado em 2012

Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-α

Por Lum, Hillary D, Buhtoiarov, Ilia N, Schmidt, Brian E, Berke, Gideon, Paulnock, Donna M, Sondel, Paul M, Rakhmilevich, Alexander L
Publicado em 2006

Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages

Por Buhtoiarov, Ilia N, Sondel, Paul M, Wigginton, Jon M, Buhtoiarova, Tatiana N, Yanke, Eric M, Mahvi, David A, Rakhmilevich, Alexander L
Publicado em 2011

Enhanced T cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice

Por Johnson, Erik E., Buhtoiarov, Ilia N., Baldeshwiler, Mark J., Felder, Mildred A.R., Van Rooijen, Nico, Sondel, Paul M., Rakhmilevich, Alexander L.
Publicado em 2011

Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect Against Murine Colon Adenocarcinoma

Por Johnson, Erik E., Yamane, Brett H., Buhtoiarov, Ilia N., Lum, Hillary D., Rakhmilevich, Alexander L., Mahvi, David M., Gillies, Stephen D., Sondel, Paul M.
Publicado em 2009

Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion

Por Russ, Andrew J., Xu, Kyle, Wentworth, Lucy, Alam, Sheeba, Meyers, Justin V., Macklin, Michael D., Rakhmilevich, Alexander L., Rajamanickam, Victoria, Suresh, M., Cho, Clifford S.
Publicado no Cell Immunol (2011)

Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects

Por Rakhmilevich, Alexander L., Baldeshwiler, Mark J., Van De Voort, Tyler J., Felder, Mildred A. R., Yang, Richard K., Kalogriopoulos, Nicholas A., Koslov, David S., Van Rooijen, Nico, Sondel, Paul M.
Publicado em 2012

Effective combination of innate and adaptive immunotherapeutic approaches in a mouse melanoma model

Por Rakhmilevich, Alexander L., Felder, Mildred, Lever, Lauren, Slowinski, Jacob, Rasmussen, Kayla, Hoefges, Anna, Van De Voort, Tyler J., Loibner, Hans, Korman, Alan J., Gillies, Stephen D., Sondel, Paul M.
Publicado no J Immunol (2017)

Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy

Por Soto, Brenda L., Hank, Jacquelyn A., Darjatmoko, Soesiawati R., Polans, Arthur S., Yanke, Eric M., Rakhmilevich, Alexander L., Seo, Songwon, Kim, KyungMann, Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Publicado em 2011

Intratumoral Immunocytokine Treatment Results in Enhanced Antitumor Effects

Por Johnson, Erik E., Lum, Hillary D., Rakhmilevich, Alexander L., Schmidt, Brian E., Furlong, Meghan, Buhtoiarov, Ilia N., Hank, Jacquelyn A., Raubitschek, Andrew, Colcher, David, Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Publicado em 2008

Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting

Por Buhtoiarov, Ilia N., Neal, Zane C., Gan, Jacek, Buhtoiarova, Tatiana N., Patankar, Manish S., Gubbels, Jennifer A. A., Hank, Jacquelyn A., Yamane, Brett, Rakhmilevich, Alexander L., Reisfeld, Ralph A., Gillies, Stephen D., Sondel, Paul M.
Publicado em 2011

Intratumoral hu14.18–IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention

Por Yang, Richard K., Kalogriopoulos, Nicholas A., Rakhmilevich, Alexander L., Ranheim, Erik A., Seo, Songwon, Kim, KyungMann, Alderson, Kory L., Gan, Jacek, Reisfeld, Ralph A., Gillies, Stephen D., Hank, Jacquelyn A., Sondel, Paul M.
Publicado em 2012

Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells...

Por Yang, Richard K., Kalogriopoulos, Nicholas A., Rakhmilevich, Alexander L., Ranheim, Erik A., Seo, Songwon, Kim, KyungMann, Alderson, Kory L., Gan, Jacek, Reisfeld, Ralph A., Gillies, Stephen D., Hank, Jacquelyn A., Sondel, Paul M.
Publicado em 2013